Winbp-Trio 20 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil (20 mg), Amlodipine (5 mg), and Hydrochlorothiazide (12.5 mg). Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, resulting in vasodilation and reduced peripheral vascular resistance. Hydrochlorothiazide is a thiazide diuretic that promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to blood volume reduction and antihypertensive effects. The combination of these three agents provides a complementary mechanism of action targeting multiple pathways involved in hypertension, offering enhanced blood pressure control in patients inadequately managed by monotherapy or dual therapy. Winbp-Trio 20 is indicated for the treatment of essential hypertension to reduce the risk of cardiovascular events such as stroke and myocardial infarction. It should be used under medical supervision with regular monitoring of blood pressure, renal function, and electrolytes to ensure efficacy and safety.